Q4 2024 Earnings Call Transcript February 11, 2025 Arvinas, Inc. beats earnings expectations. Reported EPS is $-0.63, ...

Dr. Marwan G. Fakih explains that KRAS mutations, found in 45% of patients with colorectal cancer, include the rare KRAS G12C mutation, leading to Lumakras approval.

Phase I clinical trials are the first step in testing a new treatment or combination of treatments. These trials often ...

"At Edible Garden, sustainability is more than just a goal—it is a core principle that guides everything we do," said Jim Kras, CEO of Edible Garden. "The introduction of our curb-side recyclable pot ...

Genprex’s (GNPX) research collaborators at a major cancer research center in Houston, Texas have published a new study which used the company’s ...

In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...

This important study demonstrates the potential of synthetic gene circuits to detect and target aberrant RAS activity in cancer cell lines. The circuit design is novel and the evidence supporting the ...

AI creates anti-cancer molecules for proteins that previously could not be targeted pharmacologically by leveraging quantum ...

Belvidere-based Edible Garden is bringing something new to the table. After a successful pilot production, the hydroponic ...

The research uncovers key genetic mutations that affect cancer treatment responses and develops a predictive tool for ...

Dr. Marwan G. Fakih discussed the FDA approval of Lumakras with Vectibix for third-line treatment of KRAS G12C-mutated ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...